



INDEPENDENT AUDITOR'S REPORT

To

Board of Directors,
Centre for Cellular and Molecular Platforms

OPINION

We have audited the financial statements of **The Novo Nordisk Foundation**, Centre for Cellular and Molecular Platforms (the Foundation) which comprise the Balance Sheet as at March 31, 2022, and the Income and Expenditure account for the year ended on that date.

In our opinion, and to the best of our information and according to the explanations given to us, the accompanying financial statement give a true and fair view of the financial position of the Foundation as at March 31, 2022 and its financial performance for the year then ended in accordance with the Accounting Standards issued by Institute of Chartered Accountants of Indian (ICAI).

BASIS FOR OPINION

We conducted our audit in accordance with the Standards on Auditing (SAs) issued by ICAI. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statement section of our report. We are independent of the Foundation in accordance with the Code of Ethics issued by the ICAI and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENT

The foundation's management is responsible for the preparation and fair presentation of the financial statement that give a fair view of financial statements of the Foundation in accordance with the accounting principles generally accepted in India. This responsibility also includes design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring accuracy and completeness of accounting records, relevant to the preparation and fair presentation of the financial statements that give a true and fair view are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENT

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from





error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

For GRSM & Associates
Chartered Accountants
FRN: 000863S


Natesh K N
Partner
M. No.: 231782



UDIN: 22231782ATNIOT1666
Date: 21-09-2022
Place: Bengaluru

CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
 Incorporated under Section 25 of the Companies Act, 1956 (Corresponding to Section 8 of Companies Act, 2013)
NNF

| Balance sheet as at 31 March 2022 | | |
|--------------------------------------|-------|--------------------|
| | Notes | 31 March 2022 |
| <u>EQUITY AND LIABILITIES</u> | | |
| Shareholders' funds | | |
| Reserves and surplus | 1 | 119,450,966 |
| Non-current Liabilities | | |
| - | | |
| Current liabilities | | |
| - | | |
| Total Equity and Liabilities | | 119,450,966 |
| <u>ASSETS</u> | | |
| Non-current Assets | | |
| Property Plant & Equipments | 2 | 66,321,352 |
| Non Current Investments | 3 | 10,000,000 |
| Long Term Loans And Advances | 4 | 28,640,376 |
| Current assets | | |
| Cash and bank balances | 5 | 14,488,118 |
| Short Term Loans And Advances | 6 | 1,120 |
| | | 119,450,966 |

Significant accounting policies and notes to the accounts

The schedules referred to above form an integral part of the financial statements

In terms of our attached report of even date.

for M/s GRSM & Associates
 Chartered Accountants
 Firm Regn No. 000863S

for and on behalf of the Board


Najesh K N
 Partner
 Membership No: 231782




Prof. Satyajit Mayor
 Director


Dr. Taslimarif Saiyed
 Director


Wg Cdr K F James (Retd)
 General Manager - Finance & Admin

Place : Bangalore
 Date :

CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS

Incorporated under Section 25 of the Companies Act, 1956 (Corresponding to Section 8 of Companies Act, 2013)
NNF

| Income and expenditure account for the year ended 31 March 2022 | | |
|---|-------|------------------|
| | Notes | 31 March 2022 |
| INCOME | | |
| Grant in Aid | | 4,623,750 |
| Other income | 7 | 1,344,647 |
| Total Income (A) | | 5,968,397 |
| EXPENDITURE | | |
| Employee Benefit Expenses | 8 | 3,085,998 |
| Depreciation | | 2,116,538 |
| Less: Transferred from Capital Reserve | | <u>2,116,538</u> |
| Other Expenses | 9 | 1,614,895 |
| Total Expenses (B) | | 4,700,893 |
| Excess of income over expenditure before tax (A-B) | | 1,267,504 |
| Tax expenses | | |
| - current tax | | - |
| - deferred tax liability / (asset) | | - |
| Excess of income over expenditure for the year | | 1,267,504 |

Significant accounting policies and notes to the accounts

The schedules referred to above form an integral part of the financial statements

In terms of out attached report of even date

for M/s GRSM & Associates
Chartered Accountants
Firm Regn No: 000863S

for and on behalf of the Board


Natesh K N
Partner
Membership No. 231782




Prof. Satyajit Mayor
Director


Dr. Taslimarif Saiyed
Director


Wg Cdr K F James (Retd)
General Manager - Finance & Admin

Place : Bangalore
Date :

CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS

Incorporated under Section 25 of the Companies Act, 1956 (Corresponding to Section 8 of Companies Act, 2013)
The Rockefeller Foundation

Notes to the Accounts

31 March 2022

₹

1. Reserves and surplus

Unutilised Capital Grant

| | |
|---|-------------------------------|
| Opening balance | - |
| Add: Grants received during the year | 120,300,000 |
| Less: Transferred to capital reserve on utilisation | 68,437,890 |
| | <hr/> <hr/> 51,862,110 |

Capital Reserve

| | |
|--|-------------------------------|
| Opening balance | - |
| Add: Capital grant relating to acquisition of assets transferred from unutilised capital | 68,437,890 |
| Less: Transferred to Income and expenditure statement to offset depreciation | 2,116,538 |
| | <hr/> <hr/> 66,321,352 |

Surplus / (Deficit) in Income & Expenditure account

| | |
|---|--------------------------------|
| Opening balance | - |
| Add: Excess of income over expenditure for the year | 1,267,504 |
| | <hr/> <hr/> 1,267,504 |
| Total | <hr/> <hr/> 119,450,966 |

3. Non Current Investments

| | |
|--------------------------|-------------------------------|
| Fixed Deposit with banks | 10,000,000 |
| | <hr/> <hr/> 10,000,000 |

4. Long term Loans And Advances

| | |
|------------------|-------------------------------|
| Capital Advances | 28,640,376 |
| | <hr/> <hr/> 28,640,376 |



5. Cash and bank balances

| | |
|-------------------------------|-------------------|
| Cash in hand | - |
| Balances with scheduled banks | 14,488,118 |
| - in Saving Account | 14,488,118 |
| | 14,488,118 |

6. Short term loans and Advances

| | |
|--------------------------|--------------|
| Other loans and advances | 1,120 |
| | 1,120 |

7. Other Income

| | |
|-------------------|------------------|
| Interest received | 1,344,647 |
| | 1,344,647 |

8. Employee Benefit Expenses

| | |
|--------|------------------|
| Salary | 3,085,998 |
| | 3,085,998 |

9. Operating expenses

| | |
|-----------------------------|------------------|
| Bank Charges | 12,157 |
| Documentation and Reporting | 197,488 |
| Overhead | 1,405,250 |
| | 1,614,895 |



4. Property Plant & Equipment

| Description | Depreciation rate | Gross block | | | Depreciation | | | Net block | | | |
|--------------|-------------------|--------------|---------------------------|-----------|-------------------|--------------|------------------------|-----------|------------------|---------------|-------------------|
| | | 1 April 2021 | Additions/ adjustments | Deletions | 31 March 2022 | 1 April 2021 | Charge for the year | Deletions | 31 March 2022 | 31 March 2021 | 31 March 2022 |
| Equipments | | - | 68,437,890 | - | 68,437,890 | - | 2,116,538 | - | 2,116,538 | - | 66,321,352 |
| TOTAL | | - | 68,437,890 | - | 68,437,890 | - | 2,116,538 | - | 2,116,538 | - | 66,321,352 |

Note* Stright Line Method of Depreciation is followed and the usefull life of laboratory equipment is 10 years has per Company's Act



Breakup

| Date of Purchase | value of Laboratory equipment | Depreciation |
|------------------|----------------------------------|------------------|
| 24/07/2021 | 4,550,000 | 312,890.41 |
| 21/10/2021 | 14,278,000 | 633,708.49 |
| 17/11/2021 | 1,441,537 | 53,317.12 |
| 24/12/2021 | 33,838,828 | 908,549.35 |
| 07/02/2022 | 14,329,525 | 208,072.55 |
| Total | 68,437,890 | 2,116,538 |

31/03/2022
251
162
135
98
53